Form 4: NeuroOne Medical Technologies CEO David Rosa Disposes of Shares to Cover Tax Obligations
SEC Form 4 Filing
NeuroOne Medical Technologies CEO David Rosa disposed of 2,239 shares of common stock on January 31, 2025, to cover tax obligations arising from a previous transaction.
Summary
- On January 31, 2025, David A. Rosa, CEO and President of NeuroOne Medical Technologies Corp, disposed of 2,239 shares of common stock.
- The transaction was executed at a price of $1.15 per share.
- The disposal was to cover tax obligations.
- Following the transaction, Rosa directly owns 1,135,072 shares of NeuroOne Medical Technologies Corp.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction to cover tax obligations, and the CEO still holds a significant number of shares.
Industry Context
This is a routine disclosure related to insider transactions. It's common for executives to sell shares to cover tax obligations, and the market typically views these transactions in the context of the executive's overall holdings and the company's performance.
Stakeholder Impact
- The disposal of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of transaction: David Rosa disposed of shares. |
| 02/04/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, NeuroOne Medical Technologies, NMTC, David Rosa, Stock Disposal, Insider Trading, Beneficial Ownership, Tax Obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.